Author Page for Yao Wang

Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22 T Cell Therapy in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Number of pages: 28 Posted: 20 Jul 2019

Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Bio-Therapeutic, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Department of Bio-Therapeutic, Government of the People's Republic of China - Department of Molecular Biology and Immunology and Zhejiang University - Department of Medical Oncology

Downloads 105 (669,616)

Abstract:

2.

CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial

Number of pages: 57 Posted: 18 Jan 2020

Hanren Dai, Chuan Tong, Fan Zhao, Meixia Chen, Yelei Guo, Deyun Chen, Xiao Han, Pingping Shen and Yao Wang

Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Nanjing University, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Nanjing University - Comprehensive Cancer Centre and Government of the People's Republic of China - Department of Molecular Biology and Immunology

Downloads 79 (809,932)

Abstract:

3.

Efficacy, Safety and Biomarker Analysis of CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial

Number of pages: 19 Posted: 05 Feb 2020

Hanren Dai, Chuan Tong, Fan Zhao, Meixia Chen, Yelei Guo, Deyun Chen, Xiao Han, Pingping Shen and Yao Wang

Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Brandeis University - Department of Chemistry, Government of the People's Republic of China - Chinese PLA General Hospital, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Government of the People's Republic of China - Department of Molecular Biology and Immunology, Nanjing University - Comprehensive Cancer Centre and Government of the People's Republic of China - Department of Molecular Biology and Immunology

Downloads 50 (1,063,489)

Yao Wang

Government of the People's Republic of China - Department of Molecular Biology and Immunology

3

234

0

Scholarly Papers (3)

Bispecific Chimeric Antigen Receptor Targeting Both CD19 and CD22 T Cell Therapy in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Abstract:

CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial

Abstract:

Efficacy, Safety and Biomarker Analysis of CD133-Directed CAR T Cells in Advanced Hepatocellular Carcinoma: A Single-Arm, Open-Label, Phase II Trial

Abstract: